The present invention relates to a pharmaceutical composition containing one or more quinazoline compounds as an active ingredient, which has antagonistic activity against serotonin 5-HT.sub.3A and is effective for the prevention and treatment of central nervous system (CNS) diseases, including emesis, nausea, alcoholism, drug abuse, depression, compulsive neurosis, anxiety, seizure, Alzheimer's disease, Parkinson's disease, Huntington's chorea, psychosis, schizophrenia, suicidal tendency, sleep disorder, appetite disorder and migraine.

Nam; Ghil Soo

Rhim; Hye Whon

Pae; Ae Nim

Choo; Hyun Ah

Choi; Kyung Il

Nah; Seung Yeol

Korea Institute of Science and Technology

Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist

Compounds which are non-natural galanin receptor ligands are disclosed. The ligands are of small size, have agonist or antagonist galanin activity and may cross the blood-brain barrier to displace galanin from galanin receptors. The ligands are useful as medicaments for treatment of convulsions (e.g. in epilepsy), diseases and disorders related to endocrinology (e.g., growth hormone, insulin or prolactin release), tumors expressing galanin receptors, feeding disorders pain, allodynia, psychiatric disorders such as depression (involving e.g., noradrenaline or serotonin), cognitive disorders (e.g. Alzeimer's disease), and the like.

Kemia, Inc.

Non-natural galanin receptor ligands

A transgenic, non-human animal model is disclosed which lacks receptors which mediate some of the central nervous system (CNS) actions of serotonin. The animal is preferably from a genus selected from the group consisting of Mus (e.g., mice), Rattus (e.g., rats), Oryctologus (e.g., rabbits) and Mesocricetus (e.g., hamsters). More preferably the animal is a mouse which lacks 5HT.sub.2c receptors. Animals lacking such receptors are overweight due to abnormal control of feeding behavior and are prone to spontaneous death from seizures. Thus, such animals provide an animal model for the testing of drugs which are potentially useful in the treatment of eating disorders and diseases such as epilepsy which result in seizures.

The Regents of the University of California

Transgenic animal model for testing drugs for treating eating disorders and epilepsy

serotonin

seizures

serotonin/seizures

Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist

Non-natural galanin receptor ligands

Transgenic animal model for testing drugs for treating eating disorders and epilepsy

Database tanaman obat terlengkap yang didukung oleh sains